Clinical trial · Interventional
Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
Resilience Enhancement Utilizing an Electronic Frailty Index-Directed Care Pathway for Older Adults Receiving Chemotherapy (RESILIENCE-e): A Prospective Single-Arm Interventional Study
NCT07175376CI-TRIAL-00116695recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemotherapy | — | UNRESOLVED | — |
| Frail | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Supportive Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants 65 years or older with active cancer diagnosis and planned chemotherapy
- description
- Participants aged 65 or older with an active cancer diagnosis who are planned to receive chemotherapy and are eFI pre-frail or frail. Participants will be provided with results and education regarding baseline assessments and offered referrals for supportive care interventions to decrease chemotherapy toxicity
- interventionNames
- Other: Supportive Care
Primary outcomes (3)
- measure
- Recruitment rate
- timeFrame
- Enrollment
- description
- The proportion of patients who are enrolled out of the total number of eligible patients approached for enrollment
- measure
- Retention rate
- timeFrame
- At 12 weeks after initiation of standard of care chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Patients with cancer: * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥ 65 years at the time of enrollment. * Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic/immune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent. * eFI pre-frail or frail status (available in EHR; defined as eFI \> 0.10) within 30 days before enrollment. * Ability to read and understand the English language Providers: * Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment. Exclusion Criteria: Patients: * Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator. * Chemotherapy planned at a facility outside the Atrium Health system. * Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).
References
Publications (0)
Data not yet available
No reference posted for this study.